(Q36478656)

14 August 2017

1 reference

title

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy (English)

1 reference

convection-enhanced delivery

14 August 2017

main subject

0 references

author name string

Mitomu Kioi

1

1 reference

14 August 2017

Syed R Husain

2

1 reference

14 August 2017

David Croteau

3

1 reference

14 August 2017

Sandeep Kunwar

4

1 reference

14 August 2017

Raj K Puri

5

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Technology in Cancer Research and Treatment

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

239-250

1 reference

Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Immunotoxin therapy for CNS tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

New strategy developments in brain tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Non-cytotoxic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Immunotoxins in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Recombinant toxins as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

The role of IL-13 and its receptor in allergy and inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-13: central mediator of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

21 January 2018

IL-13 effector functions

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Genes that mediate breast cancer metastasis to lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-13 receptor as a unique target for anti-glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Targeted therapy for brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Radioimmunotherapy of cancer: clinical studies and limiting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Immunotoxins against solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Novel anti-brain tumor cytotoxins specific for cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

A circularly permuted recombinant interleukin 4 toxin with increased activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

Expression of Interleukin 13 Receptor in Glioma and Renal Cell Carcinoma: IL13Rα2 as a Decoy Receptor for IL13

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500307

10.1177/153303460600500307

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference